Comments on: Life sciences briefing: Wednesday, Sept. 26, 2007 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/ News About Tech, Money and Innovation Tue, 24 Nov 2009 05:47:06 +0000 http://wordpress.org/?v=2.8.5 hourly 1 By: VentureBeat » Life sciences briefing: Monday, Dec. 31, 2007 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-707884 VentureBeat » Life sciences briefing: Monday, Dec. 31, 2007 Tue, 01 Jan 2008 04:17:21 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-707884 [...] Mitralign is yet another device startup hoping to treat heart failure by repairing the mitral valve, which regulates the flow of blood through the heart’s left chambers. The company doesn’t seem to have divulged much about it’s particular technological approach yet, but we previously covered two other startups with similar aims, eValve and Cardiosolutions, here and here. [...] [...] Mitralign is yet another device startup hoping to treat heart failure by repairing the mitral valve, which regulates the flow of blood through the heart’s left chambers. The company doesn’t seem to have divulged much about it’s particular technological approach yet, but we previously covered two other startups with similar aims, eValve and Cardiosolutions, here and here. [...]

]]> By: Reyab Nivlem http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-663154 Reyab Nivlem Tue, 04 Dec 2007 08:34:02 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-663154 Does anyone know if GlobeImmune has any drug success prior to these tests that they are working on now? Reyab Nivlem http://hepatitiscsymptoms.blogspot.com Does anyone know if GlobeImmune has any drug success prior to these tests that they are working on now?

Reyab Nivlem
http://hepatitiscsymptoms.blogspot.com

]]> By: VentureBeat » Intelligent Bio-Systems stakes out new ground in the gene race — a $5,000 genome by late next year http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-655650 VentureBeat » Intelligent Bio-Systems stakes out new ground in the gene race — a $5,000 genome by late next year Thu, 29 Nov 2007 02:14:22 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-655650 [...] at several of the newer upstarts in the field, most recently Complete Genomics and Bionanomatrix, Genome Corp. (seventh item), and Genomic Diagnostics (fourth [...] [...] at several of the newer upstarts in the field, most recently Complete Genomics and Bionanomatrix, Genome Corp. (seventh item), and Genomic Diagnostics (fourth [...]

]]> By: VentureBeat » Evalve pulls in $60M, heating up heart-valve implant race http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-652612 VentureBeat » Evalve pulls in $60M, heating up heart-valve implant race Tue, 27 Nov 2007 18:47:44 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-652612 [...] Investors included BBT Fund, Delphi Ventures, New Enterprise Associates, Split Rock Partners and Abbott Laboratories. Evalve isn’t alone in this market, although it appears to be ahead of one rival we’ve previously covered, Cardiosolutions (see our coverage). [...] [...] Investors included BBT Fund, Delphi Ventures, New Enterprise Associates, Split Rock Partners and Abbott Laboratories. Evalve isn’t alone in this market, although it appears to be ahead of one rival we’ve previously covered, Cardiosolutions (see our coverage). [...]

]]> By: VentureBeat » Life sciences briefing: Monday, Oct. 22, 2007 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-591460 VentureBeat » Life sciences briefing: Monday, Oct. 22, 2007 Tue, 23 Oct 2007 01:21:29 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-591460 [...] be launched on Eurolist by Euronext Brussels. You can find our previous coverage of the company here and [...] [...] be launched on Eurolist by Euronext Brussels. You can find our previous coverage of the company here and [...]

]]> By: VentureBeat » Medical-device funding is doing fine — but VCs are suddenly fleeing biotechnology http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-590970 VentureBeat » Medical-device funding is doing fine — but VCs are suddenly fleeing biotechnology Mon, 22 Oct 2007 18:10:53 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-590970 [...] hedge funds among its investors, including Wexford Capital. (See a detailed list in our coverage here.) Tengion, which raised $33 million last month, was backed by non-VC financiers such as Deerfield [...] [...] hedge funds among its investors, including Wexford Capital. (See a detailed list in our coverage here.) Tengion, which raised $33 million last month, was backed by non-VC financiers such as Deerfield [...]

]]> By: VentureBeat » Life sciences briefing: Thursday, Oct. 11, 2007 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-574352 VentureBeat » Life sciences briefing: Thursday, Oct. 11, 2007 Thu, 11 Oct 2007 19:05:11 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-574352 [...] Bind Biosciences is one of several startups hoping to tailor the biological, physical and chemical properties of nanoparticles in ways that will cause them to hone in on particular tissues or protein targets. By attaching drug molecules to these nanoparticles, it should theoretically be possible to turn them into a new version of “smart-bomb” targeted therapies. Other startups at work in this space that we’ve written about include Tempo Pharmaceuticals and Carigent Therapeutics (see our coverage here and here). [...] [...] Bind Biosciences is one of several startups hoping to tailor the biological, physical and chemical properties of nanoparticles in ways that will cause them to hone in on particular tissues or protein targets. By attaching drug molecules to these nanoparticles, it should theoretically be possible to turn them into a new version of “smart-bomb” targeted therapies. Other startups at work in this space that we’ve written about include Tempo Pharmaceuticals and Carigent Therapeutics (see our coverage here and here). [...]

]]> By: VentureBeat » Life sciences briefing: Wednesday, Oct. 10, 2007 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/comment-page-1/#comment-572350 VentureBeat » Life sciences briefing: Wednesday, Oct. 10, 2007 Wed, 10 Oct 2007 17:53:41 +0000 http://venturebeat.com/2007/09/26/life-sciences-briefing-wednesday-sept-26-2007/#comment-572350 [...] Targanta priced as many as 5.8 million shares at $10 apiece, below its $12 to $14 range (see our coverage), raising the company a maximum of $57.5 million — down considerably from the $92.6 million [...] [...] Targanta priced as many as 5.8 million shares at $10 apiece, below its $12 to $14 range (see our coverage), raising the company a maximum of $57.5 million — down considerably from the $92.6 million [...]

]]>